Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology

Presentation to provide overview of Phase 2 T-CALM study design,
results and clinical path forward

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cavion, Inc., a leading clinical stage biotechnology company committed
to developing novel therapeutics for people with neurological diseases,
announced today that the results of the Phase 2 study of its lead
compound, CX-8998, for essential tremor will be featured in a platform
presentation during the American Academy of Neurology 71st Annual
Meeting, May 4 to May 10, 2019 in Philadelphia, PA.

Cavion is developing oral small molecules designed to selectively
modulate T-type calcium channel activity in the central nervous system,
acting as a biological “pacemaker” to help restore the brain’s natural
rhythms. The company’s lead candidate CX-8998 is a first-in-class T-type
calcium channel modulator and is the most advanced late-stage small
molecule currently in development for essential tremor. CX-8998 was
evaluated in the T-CALM Study, a Phase 2, double-blind,
placebo-controlled clinical trial of 95 patients with essential tremor
conducted at 25 sites across the United States. Patients were randomized
to one of two treatment arms, receiving either placebo or CX-8998. A
majority of subjects (64%) took study drug on top of certain standard of
care anti-tremor medications.

“I am pleased to present the results of our Phase 2 T-CALM
proof-of-concept study of CX-8998 in essential tremor at the annual
Academy meeting,” said Margaret Lee, Cavion Senior Vice President,
Preclinical and Translational Sciences. “We look forward to discussing
our clinical path forward as we work to address the unmet need in this
devastating disorder that can rob people of their quality of life and
has not seen any new approved drug therapies in more than three decades.”

The T-CALM study will be featured during Session S4: Clinical Trials in
Movement Disorders in a platform session on Sunday, May 5:

“Efficacy Result from a Phase 2, Double-Blind,
Placebo-Controlled Study of CX-8998 a State-Dependent T-Type Calcium
(Cav3) Channel Modulator in Essential Tremor Patients (T-CALM)”

Session time: 2:17 pm
Session name: S4: Clinical Trials in Movement
Disorders
Program Number: S4.008

About Cavion, Inc.

Cavion,
Inc. is a privately held clinical stage biotechnology company
creating therapies aimed at modulating the T-type calcium channel for
the treatment of chronic and rare neurological diseases. Cavion’s
portfolio of T-type calcium channel modulators is being developed to
restore the brain’s natural rhythms in a variety of neurological
diseases such as essential tremor, Parkinson’s disease tremor,
neuropathic pain, and epilepsy with absence seizures.

About Essential Tremor

About 10 million Americans and 42 million people worldwide are affected
by essential tremor (ET), the most common movement disorder. ET is a
progressive neurodegenerative disease that ranges from mild to fully
debilitating, with significant effects on people’s quality of life and
activities of daily living, such as eating and drinking, dressing,
writing and typing. The condition can lead to social embarrassment,
phobia, anxiety, and depression. With no new drugs approved for more
than three decades, there is a need for new and effective options for
patients with ET.

Forward-Looking Statement

This press release contains forward-looking statements that are subject
to risks and uncertainties and includes statements that are not
historical facts. Actual results could differ significantly from results
discussed. Cavion, Inc. disclaims any intent or obligation to update
forward-looking statements, except as required by law.

Contacts

Lynn Blenkhorn
[email protected]
508-851-0930

Susan Klees
[email protected]
(434)
466-8930